Basic Information
LncRNA/CircRNA Name | MALAT1 |
Synonyms | MALAT1, HCN, LINC00047, NCRNA00047, NEAT2, PRO2853 |
Region | GRCh38_11:65497688-65506516 |
Ensemble | ENSG00000251562 |
Refseq | NR_002819 |
Classification Information
Regulatory Mechanism | Biological Function | Clinical Application | |||
---|---|---|---|---|---|
TF | Immune | Survival | |||
Enhancer | Apoptosis | apoptosis | Drug | Cisplatin | |
Variant | Cell Growth | Circulating | |||
MiRNA | EMT | Metastasis | |||
Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
Cancer Name | non small cell lung cancer |
ICD-0-3 | C34 |
Methods | qPCR, Western blot, Luciferase reporter assay, RNAi, other |
Sample | NSCLC tissues and cell lines (A549 and H1299) |
Expression Pattern | up-regulated |
Function Description | MALAT1 level was increased in A549rCDDP cells compared with the parental A549 cells. Silencing of MALAT1 sensitized A549rCDDP cells to cisplatin treatment, while overexpression of MALAT1 in A549 cells decreased their sensitivity towards cisplatin. Through analysis of the gene expression in patient samples, a decrease in miR-145 and an increase in Kruppel-like factor 4 (KLF4) in tumor tissues compared with adjacent normal tissues was observed. A negative association between MALAT1 and miR-145 was also identified in A549 cells and A549rCDDP cells. Furthermore, reverse transcription quantitative polymerase chain reaction and western blotting identified that KLF4 was positively and negatively regulated by MALAT1 and miR-145, respectively. The direct regulatory association between MALAT1 and miR-145 and the target gene KLF4 was additionally confirmed using a luciferase reporter assay. Knockdown of MALAT1 reversed cisplatin resistance in A549rCDDP cells. |
Pubmed ID | 30250547 |
Year | 2018 |
Title | Increased MALAT1 Expression Contributes to Cisplatin Resistance in Non-Small Cell Lung Cancer |
External Links
Links for MALAT1 | GenBank HGNC NONCODE |
Links for non small cell lung cancer | OMIM COSMIC |